Cipla has been approved by The Drug Controller
General of India to sell anti-COVID-19 drug favipiravir for the treatment of
corona-virus, Cipla said India as corona-virus infections in the world's third
position at this time. The Indian regulatory permitted Cipla accelerated
approval to produce and marketing favipiravir in an effort to meet the unmet
need for COVID-19 treatment options in the country, the company said. And the other hand other drug company which include Glenmark Pharmaceuticals are racing
to supply generic versions of favipiravir, originally developed by Japan's
Fujifilm Holdings for treating influenza.
India reported over 48,916 fresh cases of the
novel coronavirus with 757 new deaths on Saturday, the total number of
coronavirus infections in India crossed the 13 lakh-mark to reach 13.36.861,
marking the biggest daily surge in cases, as officials in some states
complained of shortages of vital drugs for those hospitalized.
Cipla said that it will launch Favipirvir in
the market in the first week of August under the name of "Ciplanza",
which is priced at INR 68 per tablet. Separately, much smaller Indian pharma
company Jenburkt Pharmaceuticals said it would launch its own version of
favipiravir, it's priced at 39 rupees per tablet. in the meantime, sells a
tablet of favipiravir for 75 rupees, with a patient approx requiring 122
tablets over 14 days for a treatment course, the company said.
Posts
.webp)
No comments: